Research Library — Page 120 | Reta Compare

3563 research articles. Page 120 of 143.

Articles

• Exploring the Potential of a Quad-Agonist Combination: GLP-1, GIP, Glucagon, and GDF15
• GLP-1 and Amylin Dual Agonists: Implications for Quad-Agonist Development
• GLP-1 and Glucagon Dual Agonists: A Foundation for Future Triple and Quad Therapies
• GLP-1 + GIP + Glucagon Triple Agonists: Retatrutide as the Benchmark for Future Multi-Agonist Therapies
• Adding Amylin to Triple Agonists: Mechanistic Synergy Explained
• FGF21 and Incretin Combinations: Enhancing Hepatic and Metabolic Outcomes
• Y2 Receptor Agonism in Multi-Receptor Obesity Drugs
• Exploring the GDF15 Pathway in Next-Generation Obesity Drugs
• Activin/Myostatin Pathway as a Target in Next-Gen Obesity Drugs
• Penta-Agonist Concept: Integrating GLP-1, GIP, Glucagon, Amylin, and FGF21 in a Single Molecule
• Exploring the Penta-Agonist Concept: GLP-1, GIP, Glucagon, Amylin, and Y2 Receptor Interplay
• Penta-Agonist Concept: GLP-1, GIP, GCG, FGF21, and Y2 in Obesity and Metabolic Disorders
• The Current Landscape of Penta-Agonists in Obesity and Metabolic Drug Development
• HM15275 (Hanmi): Quad-Agonist Candidate for Obesity
• HRS-7535 (Hengrui): An Oral Small-Molecule Multi-Receptor Agonist for Obesity and Metabolic Disorders
• IBI-3034 (Innovent): Advancing the Triple and Quad Agonist Pipeline from China
• Eli Lilly's Post-Retatrutide Pipeline: Future Directions Beyond LY3437943
• Novo Nordisk's Post-Semaglutide Pipeline: Amycretin and Future Multi-Agonists
• Boehringer Ingelheim Survodutide and the Path Toward Quad-Agonists
• Pfizer's Multi-Agonist Obesity Pipeline
• AstraZeneca and Eccogene: Oral GLP-1 and Future Multi-Agonists
• Roche's CT-388 and the Future of Dual and Triple Agonists
• Amgen MariTide (AMG 133): A Unique GLP-1 Agonist with GIP Antagonism
• Viking Therapeutics VK2735: A Dual GLP-1/GIP Agonist with Potential for Triple Action
• Structure Therapeutics GSBR-1290: Oral GLP-1 With Pipeline Expansion